{
    "nct_id": "NCT03030248",
    "official_title": "Randomized Double Blind Controlled Trial for the Treatment of Nucleic Acid Amplification Test (NAAT)+/Toxin Enzyme Immunoassay (EIA)- Clostridium Difficile in the Hematology Oncology Population",
    "inclusion_criteria": "* Patients admitted to the hematology oncology inpatient units at Froedtert Memorial Lutheran Hospital\n* New onset of diarrhea during hospitalization\n* C. difficile clinical testing showing NAAT positive EIA negative results\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Being unable to consent for self\n* Inability to take enteral medications\n* Unwillingness to enroll in study\n* Patient has a documented allergy to vancomycin\n* Patient has a documented life expectancy shorter than treatment course (14 days)\n* Patient is unwilling or unable to provide stool samples in the outpatient setting after discharge\n* Diagnosis of C. difficile colitis [NAAT (+) and toxin EIA (+) within 3 months of enrollment).\n* New onset of abdominal distention within 24 hours prior to the onset of diarrhea during index admission\n* Presence of toxic megacolon\n* Presence of clinical sepsis. Sepsis will be defined as a Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score of 2 points or more as per 2016 definitions\n* Pregnancy or lactating",
    "miscellaneous_criteria": ""
}